Skip to Content
Merck
  • Acute reduction of microglia does not alter axonal injury in a mouse model of repetitive concussive traumatic brain injury.

Acute reduction of microglia does not alter axonal injury in a mouse model of repetitive concussive traumatic brain injury.

Journal of neurotrauma (2014-05-07)
Rachel E Bennett, David L Brody
ABSTRACT

The pathological processes that lead to long-term consequences of multiple concussions are unclear. Primary mechanical damage to axons during concussion is likely to contribute to dysfunction. Secondary damage has been hypothesized to be induced or exacerbated by inflammation. The main inflammatory cells in the brain are microglia, a type of macrophage. This research sought to determine the contribution of microglia to axon degeneration after repetitive closed-skull traumatic brain injury (rcTBI) using CD11b-TK (thymidine kinase) mice, a valganciclovir-inducible model of macrophage depletion. Low-dose (1 mg/mL) valganciclovir was found to reduce the microglial population in the corpus callosum and external capsule by 35% after rcTBI in CD11b-TK mice. At both acute (7 days) and subacute (21 days) time points after rcTBI, reduction of the microglial population did not alter the extent of axon injury as visualized by silver staining. Further reduction of the microglial population by 56%, using an intermediate dose (10 mg/mL), also did not alter the extent of silver staining, amyloid precursor protein accumulation, neurofilament labeling, or axon injury evident by electron microscopy at 7 days postinjury. Longer treatment of CD11b-TK mice with intermediate dose and treatment for 14 days with high-dose (50 mg/mL) valganciclovir were both found to be toxic in this injury model. Altogether, these data are most consistent with the idea that microglia do not contribute to acute axon degeneration after multiple concussive injuries. The possibility of longer-term effects on axon structure or function cannot be ruled out. Nonetheless, alternative strategies directly targeting injury to axons may be a more beneficial approach to concussion treatment than targeting secondary processes of microglial-driven inflammation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Valganciclovir hydrochloride hydrate, ≥98% (HPLC)
Pricing and availability is not currently available.
Sigma-Aldrich
FragEL DNA Fragmentation Detection Kit, Fluorescent - TdT Enzyme
Pricing and availability is not currently available.
Sigma-Aldrich
Anti-NeuN Antibody (rabbit), from rabbit, purified by affinity chromatography
Pricing and availability is not currently available.